Allergic fungal rhinosinusitis (AFRS) is the most common form of fungal sinus disease. Its recurrence rate is high despite numerous strategies to prevent it. We conducted a study to assess the eff ect of systemic and topical antifungal agents-both separately and in combination-in preventing recurrence of AFRS following functional endoscopic sinus surgery (FESS). Our initial study population was made up of 50 adults who were diagnosed with AFRS by clinical, radiologic, histopathologic, and laboratory workup and who subsequently underwent FESS. Postoperatively, these patients were randomized into 5 diff erent treatment groups matched for sex, age, and socioeconomic status. Four of the groups received a diff erent antifungal regimen in addition to convenient medical treatment (CMT), while a fi ft h group served as a control. Th e antifungal regimens included oral itraconazole (group A), fl uconazole nasal spray (group B), combined oral itraconazole and nasal fl uconazole (group C), and irrigation with a fl uconazole solution through the nasal fossa (group D); the group of 10 controls (group E) received CMT only. A total of 41 patients were available for follow-up (9 mo maximum). Recurrence rates in the 5 groups were 66.7, 10.0, 14.3, 28.6, and 75.0%, respectively. Based on our fi ndings, we conclude that treatment with topical fl uconazole as either a nasal spray or an irrigation solution can signifi cantly reduce the rate of recurrence of AFRS aft er FESS.
Introduction
Most patients who present with unilateral or bilateral nasal polyps are found to have underlying fungal rhinosinusitis. Allergic fungal rhinosinusitis (AFRS) is the most common form of fungal sinus disease, and the presence of nasal polyposis is one of the criteria required for its diagnosis. 1 Over the past 2 decades, AFRS has become increasingly defi ned, and it is now believed to represent an allergic reaction to aerosolized environmental fungi, usually of the dematiaceous species, in an immunocompetent host. 2 Persistence of AFRS with a recurrence of sinonasal symptoms is common, particularly when eradication of allergic fungal mucin has been incomplete. Recurrence can occur even when a patient is clinically disease-free, presumably as a result of reexposure to fungal antigens. 3 When researchers recognized that recurrence rates were high even following functional endoscopic sinus surgery (FESS), eff orts were undertaken to prevent recurrence by prescribing adjunctive postoperative systemic antifungal therapies. However, many patients experienced little benefi t from the addition of drug therapy while experiencing adverse side eff ects. 4 As an alternative to systemic antifungal therapy, topical antifungals may hold some promise for the control of postoperative recurrence. 5, 6 However, data regarding such a line of therapy are limited. We conducted this klinger technique as described by Bera and Rao. 10 Th e surgery included endoscopic polypectomy with wide drainage and ventilation of the aff ected sinuses (middle meatal antrostomy, sphenoidotomy, and ethmoidectomy) and with removal of fungal "mud" and mucin.
Histopathologic fi ndings. Histopathologic examination of the removed polypoid tissue, allergic mucin, and adjacent sinus mucosa was performed in the Department of Pathology at Menofi ya University Hospital. Histologic sections were prepared in the usual manner and stained (1) with hematoxylin and eosin (H&E) to address pathologic abnormalities and (2) with Gomori methenamine silver (GMS) for identifi cation of fungi. Specimens that were inconclusive or negative on H&E and/or GMS staining were subjected to culture.
Ten of the 50 cases (20.0%) were suspicious for fungal infection on H&E staining. Examination with H&E revealed the following:
• extensive edema (fi gure, A); • mucinous metaplasia of the surface epithelium, thickening of the basement membrane, and heavy infi ltration by chronic infl ammatory cells, including eosinophils (fi gure, B);
• allergic mucin with its pale-blue chondroid matrix entangling both viable and degranulated eosinophils (fi gure, C); study in an attempt to contribute to the further evaluation of topical antifungal therapy for AFRS following FESS.
Patients and methods
Study population. We prospectively enrolled 50 patients-30 men and 20 women, aged 18 to 61 years (mean: 35.4)-who had presented with nasal polyposis and who had been diagnosed with AFRS on the basis of clinical, radiologic, histopathologic, and laboratory examinations. All patients had been seen at the Department of Otolaryngology at Menofi ya University Hospital between Jan. 1 and Dec. 31, 2008.
Preoperative assessments. All patients underwent clinical and endoscopic examinations, followed by computed tomography (CT) to confi rm a diagnosis of AFRS and to determine the extent of polyposis. Th e following CT fi ndings are characteristic of AFRS:
• complete opacifi cation of at least one paranasal sinus;
• expansion of the involved sinus;
• attenuation or erosion of the bone bordering the involved sinus;
• signal heterogeneity within the involved sinus;
• unilateral or asymmetric distribution of disease;
• displacement of the adjacent anatomic compartments; and
• the double-density sign. 7, 8 Each patient was assigned an AFRS score according to the radiologic staging system developed by Wise et al. 9 With this system, points are assigned for various radiologic fi ndings with respect to the extent of nasal polyposis and the degree of bone erosion. Possible scores range from 0 to 24.
All patients also had their total serum IgE level measured to evaluate type I (immediate) hypersensitivity. Serum IgE concentration was determined with an enzyme-linked fl uorescent assay (mini VIDAS; bioMérieux; Marcy-l'Étoile, France). We used the international reference value of 150 U/ml in our evaluation. Patients were classifi ed into 2 categories based on their IgE level: from 150 to 1,000 U/ml and greater than 1,000 U/ml. Surgery. All patients underwent FESS via the Messer- • hyphal fragments (fi gure, D); and • an absence of fungal invasion in the adjacent nasal mucosa.
GMS staining was positive in 20 cases (40.0%), including the 10 who had a positive H&E fi nding. Th e 30 patients (60.0%) who had a negative GMS result underwent fungal culture, and it was positive in all 30.
Postoperative therapy. All 50 patients received CMT with an oral steroid (prednisone at 60 mg/day for 6 weeks tapered over 3 weeks), a topical steroid (fl uticasone nasal spray at 2 puff s/day for 6 months), an oral antibiotic (amoxicillin/clavulanic acid at 500/125 mg three times daily for 14 days), an alkaline nasal wash (borax, sodium chloride, or sodium bicarbonate at 5 g/50 ml three times daily for 2 weeks), and an oral H 1 histamine antagonist (loratadine at 10 mg once daily for 2 weeks).
In addition, the 50 patients were randomly assigned to 1 of 5 treatment groups of 10 patients each. Th e 5 groups were matched for sex, age, and socioeconomic status. Each group received a diff erent type of postoperative antifungal regimen:
• Group A was treated with oral itraconazole at 100 mg once a day for 3 months. Patients in this group underwent monthly liver function tests to monitor the hepatic side eff ects of this drug.
• Group B received topical nasal-spray therapy with 100 mg of fl uconazole in 500 ml of normal saline solution. Patients self-administered 5 sprays of 0.5 ml each into each nostril twice daily for 3 months.
• Group C patients were given a combined systemic and topical regimen for 3 months. Th erapy consisted of oral itraconazole at 100 mg/day and topical fl uconazole in the same dosage as that used by group B.
• Group D patients returned to the hospital to be treated under local anesthesia by irrigation with a fl uconazole solution through the nasal fossa. Th is therapy was delivered once a week for 6 consecutive weeks. Th e formulation of the solution was the same as that of the nasal spray.
• Group E served as a control group and received no antifungal therapy, only CMT.
Follow-up.
Patients were monitored for recurrence for a maximum of 9 months by clinical and endoscopic examinations and CT. Recurrence rates were calculated for each group.
Statistical analysis. Data were collected, tabulated, and statistically analyzed on a personal computer with the Statistical Package for the Social Sciences soft ware (v. 11; SPSS; Chicago). Th e chi-square (χ 2 ) test, analysis of variance (ANOVA), and the Mann-Whitney U test were used in making comparisons. Diff erences were considered statistically signifi cant at p < 0.05.
Prior to antifungal treatment, there were no statistically signifi cant diff erences among the 5 groups with respect to sex, age, socioeconomic status, signs and symptoms, history of associated allergic conditions (allergic rhinitis, aspirin intolerance, and asthma), serum IgE level, and AFRS score (table 1) .
Results
Of the original group of 50 patients, 9 were lost to follow-up, leaving us with 41 evaluable patients for the fi nal analysis.
Recurrence. Among the 41 patients, 16 (39.0%) experienced a recurrence and 25 (61.0%%) did not. Recurrence rates in the 5 groups were as follows:
• group A (oral itraconazole): 6 of 9 evaluable patients (66.7%);
• group B (fl uconazole nasal spray): 1 of 10 patients (10.0%);
• group C (oral itraconazole and topical fl uconazole): 1 of 7 patients (14.3%);
• group D (fl uconazole irrigation): 2 of 7 patients (28.6%); and
• group E (no antifungal therapy): 6 of 8 patients (75.0%).
Associated factors.
Subgroup analyses revealed no statistically signifi cant diff erence in recurrence rates according to sex or age. However, recurrence rates were signifi cantly higher among patients of low socioeconomic status and among those with a history of associated allergic conditions, a serum IgE level greater than 1,000 U/ml, and a higher preoperative AFRS score (table 2) .
Discussion
AFRS is a disease of poor socioeconomic status. 11 Th is fact was borne out in our study, as 70.0% of all cases (table 1) and 93.8% of all recurrences (table 2) occurred in patients who had a low standard of living. Nasal obstruction, headache, postnasal discharge, and hyposmia/ anosmia are commonly reported presenting signs and symptoms, 12 as they were in our study (table 1) .
Diagnosis. Th e diagnosis of AFRS can be challenging because identifi cation of the inciting fungi is sometimes very diffi cult. Gross identifi cation of thick, inspissated allergic mucin during surgery is central to confi rming the diagnosis. In our study, allergic mucin was identifi ed in all subgroups. It appears on H&E staining as a paleblue, chondroid-like matrix, sometimes with entangled or degranulated eosinophils (Charcot-Leyden crystals). Th e presence of occult allergic mucin that contains fungal hyphae is responsible for recurrences of AFRS aft er surgery. 13 Four criteria for the histopathologic diagnosis of AFRS were fulfi lled in our patients:
• identifi cation of allergic mucin, either grossly or microscopically;
• mucosa that is similar in appearance to asthmatic bronchial mucosa, exhibiting, for example, edema, thickening of the basement membrane, distended mucous glands, and the presence of chronic infl ammatory cells, including plasma cells, lymphocytes, and eosinophils;
• either a positive GMS stain or, in the event of a negative GMS stain, a positive fungal culture;
• exclusion of other fungal diseases, such as invasive fungal rhinosinusitis and mycetoma, together with an absence of necrosis and granulomata. 14 In many cases of AFRS, fungal hyphae are rare, scattered, and fragmented within the allergic mucin and absent in mucosa and bone, so their identifi cation by H&E staining is usually diffi cult. In these cases, special stains such as GMS are required to identify the fungi. In our study, fungi were suspicious for AFRS in 20.0% of cases by H&E, and GMS staining was positive in 40.0% of cases. In the 60.0% of cases in which staining was negative, fungal culture was positive. Silver staining is very sensitive for the detection of fungi, but it may still be negative in an otherwise typical case of AFRS, as was reported by Allphin et al. 15 Furthermore, Javer et al found that the yield of fungal culture in AFRS patients ranged between 10 and 20% with standard culture techniques and that it might reach as high as 64% with the use of the modifi ed Mayo Clinic fungal culture technique, so a negative culture obviously does not exclude the possibility of AFRS. 16 Conversely, a positive fungal culture may merely represent the presence of saprophytic fungal growth, and therefore it does not in itself confi rm the diagnosis of AFRS. In sum, diagnosis requires a combination of fi ndings, including the clinical picture, radiologic results, histopathologic evidence (especially the appearance of allergic mucin), and laboratory testing.
Immunologic investigation is an essential tool in the assessment of AFRS. Total serum IgE levels are generally elevated in AFRS, oft en to more than 1,000 U/ml. 13, 17 However, a level as low as 100 U/ml can be considered high. 18 In our study, 80% of patients had a preoperative total IgE level greater than 1,000 U/ml, and the remaining 20% had a level greater than 150 U/ml. Moreover, an elevated level was also signifi cantly associated with recurrence, which is consistent with a fi nding reported by Schubert and Goetz. 14 However, AFRS is occasionally diagnosed in a patient whose total serum IgE level is normal, so a normal level does not exclude a diagnosis of AFRS. 13, 19 Treatment. Th e most common management strategy for AFRS is the removal of allergic mucin and debris via FESS, but recurrence remains problematic. 6, 14, 17, 20 Th e postoperative persistence of allergic mucin and fungal debris is essential in the pathogenesis of AFRS, and their persistence is responsible for the high recurrence rates seen with this disease. 13 As a result, pre-and postoperative medical therapy has been used in attempts to prevent recurrence. 6 One accepted strategy is to initiate systemic corticosteroid therapy with prednisone at 0.5 to 1 mg/kg/day 1 week before surgery to decrease intranasal infl ammation. Additionally, preoperative antibiotics can be given to lower the risk of concomitant postobstructive bacterial rhinosinusitis. In our study, oral antibiotics and oral and topical corticosteroids were given to all patients as part of CMT aft er FESS. Th e use of an oral corticosteroid for our postoperative AFRS patients yielded the same good results that have been seen in studies of patients with allergic bronchopulmonary aspergillosis, 21, 22 as well as in other studies of AFRS. 12, 23 Th e eff ect of antifungal agents in the treatment of AFRS is still a matter of controversy among researchers. Th e addition of a topical antifungal to a topical steroid has been recommended by both Ricchetti et al 24 and Jornot et al, 25 but other investigators 26 have reported that topical antifungals are not only ineff ective, but they may also worsen symptoms. In addition, systemic antifungals can exert a hepatotoxic eff ect, so a long course is risky. Th e expense, the limited amount of available data, and the potential for drug-related morbidity all may limit the use of systemic antifungal therapy as a treatment for noninvasive fungal disease. 4 Indeed, in our study, the recurrence rate for those patients who were treated postoperatively with oral itraconazole alone (group A) was 66.7%, by far the highest rate among all the groups except the control group.
Th e ineff ectiveness of oral itraconazole at 100 mg/day in our study is at variance with fi ndings by others. Javer and Chan 27 and Chan et al 28 both reported promising results with itraconazole in the management of refractory AFRS, and Rains and Mineck 29 found that the combination of itraconazole, an oral corticosteroid, a topical corticosteroid, and endoscopic sinus surgery was a safe and clinically eff ective regimen in the management of AFRS. Th e ineff ectiveness of itraconazole in our study might be attributable to the absence of tissue invasion in AFRS, which reduces the drug's concentration and hinders its access to the target. Another explanation might be that AFRS is now believed to be more of an allergic reaction than a fungal infection. 13 In the groups of patients who received a topical antifungal only (group B) and both an oral and topical antifungal (group C) in addition to CMT, the recurrence rates were only 10.0 and 14.3%, respectively. Th is fi nding supports the opinion that the addition of a topical antifungal to CMT in postoperative AFRS patients provides a reasonable benefi t in preventing recurrence. Our fi ndings in this regard correlate well with the results of a study by Jen et al, who found that 12 of 16 AFRS patients (75.0%) improved upon receiving fl uconazole nasal spray. 5 On the other hand, Weschta et al conducted a randomized, double-blind, placebo-controlled trial of the antifungal amphotericin B topically in 60 patients with chronic rhinosinusitis and found that it was ineff ective. 26 Conclusion. In conclusion, the diagnosis of AFRS must be reached via a triple approach, starting with clinical evidence, continuing with radiologic investigation, and ending with characteristic histopathologic fi ndings. Fungal culture is highly recommended when histopathology is suspicious for AFRS, even in cases of negative GMS staining. Th e use of a topical fl uconazole solution, either as a nasal spray or as an irrigant, can signifi cantly reduce the recurrence rate. Itraconazole at 100 mg/day had no signifi cant eff ect on recurrence of AFRS aft er FESS. Also, we noted that no synergy or additive benefi t in terms of preventing recurrence was gained by the addition of oral itraconazole to topical fl uconazole.
